Development of a FDA-Approved Pharmaceutical to Treat Noise-Induced Hearing Loss.

摘要

The overall objective the work reported here was designed to obtain additional pre-clinical data required to prepare the FDA Briefing Book in support of Phase 1 a and 1 b studies. The technical objectives of this study have provided important efficacy and pharmacokinetic pre- clinical data in rats in support of our application for FDA clinical trials.